Research programme: cancer therapeutics - Endocyte

Drug Profile

Research programme: cancer therapeutics - Endocyte

Alternative Names: CB-3717; EC 0531; EC 0651; EC 1812; EC 1868; EC 1977; EC 2629; EC-1744; EC1788; GARFTase inhibitors - Endocyte; PNU-159682

Latest Information Update: 28 Apr 2016

Price : $50

At a glance

  • Originator Endocyte
  • Developer Endocyte; Purdue University
  • Class CAR-T cell therapies; Cell therapies; Depsipeptides; Doxorubicins; Drug conjugates; Folic-acids; Oligopeptides; Small molecules; Taxanes
  • Mechanism of Action Folate receptor 1 antagonists; Glutamate carboxypeptidase II inhibitors; Immunostimulants; Phosphoribosylglycinamide formyltransferase inhibitors; Tubulin polymerisation inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Haematological malignancies; Prostate cancer; Solid tumours
  • Research Cancer

Most Recent Events

  • 10 Mar 2017 Endocyte announces intention to submit an IND application for EC 2629 in mid-2017
  • 10 Mar 2017 Endocyte plans a phase I trial for Cancer
  • 19 Apr 2016 Endocyte holds the global rights to the CAR and SMDC adaptors for all indications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top